- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Suven Life Sciences Limited — Updates, 16-06-2026: Press Release
16-06-2026 | 09:25 am
16-06-2026 | 09:25 am
Suven Life Sciences successfully completed Phase-1 clinical study for SUVN-I6107, a CNS disorder treatment. It demonstrated a favorable safety profile and robust CNS activity, supporting its advancement into Phase-2 development. This marks their fifth internally discovered candidate to reach clinical stage.
No comments yet. Be the first to comment!